Evidence map›Paper›PMID 30755308›Full record

ReviewTrends in cancer2019

Ushering in Integrated T Cell Repertoire Profiling in Cancer.

Ning Jiang, Alexandra A Schonnesen, Ke-Yue Ma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. AIRR Community Guide to Planning and Performing AIRR-Seq Experiments.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ning JiangDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX 78712, USA; Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA; LIVESTRONG Cancer Institutes, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA. Electronic address: jiang@austin.utexas.edu.
Alexandra A SchonnesenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
Ke-Yue MaInstitute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA.

Funding

Comprehensive Training Program in Imaging Science and InformaticsT32EB007507 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI MARKEY, MIA K, RYLANDER, HENRY GRADY · 2009 to 2024
$2.7M
An integrated therapeutic T cell receptor screening platform for adoptive cell therapy in cancerR33CA225539 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI JIANG, NING JENNY · 2018 to 2022
$1.1M
NCI NIH HHS R33 CA225539NIBIB NIH HHS T32 EB007507
6 · The paper itself

Abstract

Advances in immune profiling techniques have dramatically changed the cancer immunotherapy and monitoring landscape. High-throughput protein and gene expression technologies have paved the way for the discovery of therapeutic targets and biomarkers, and have made monitoring therapeutic response possible through the ability to independently assay the phenotype, specificity, exhaustion status, and lineage of single T cells. Although valuable insights into response profiling have been gained with current technologies, it has become evident that single-method profiling is insufficient to accurately capture an antitumor T cell response. We discuss and propose new methods that combine multiple axes of analysis to provide a comprehensive analysis of T cell repertoire in the fight against cancer.

Indexed as

HumansImmunotherapyNeoplasmsT-Lymphocyteshigh-throughput integrated single T cell profilingimmune checkpoint blockadeimmune repertoireT cells

Identifiers

PMID30755308
PMCPMC6544389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.